Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence
- PMID: 17124224
- PMCID: PMC1661741
- DOI: 10.1136/bmj.39000.486701.68
Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence
Abstract
Increasing intake of folic acid would be a relatively cheap and simple way of reducing heart disease, if it works. Can we draw a definitive conclusion from the current evidence?
Conflict of interest statement
Competing interests: ML, NJW, and DSW have interests in a combined pill (polypill) to simultaneously reduce four cardiovascular risk factors including homocysteine. NJW and ML have patents (granted and pending) on the formulation of the polypill.
Figures
Similar articles
-
[Uncertain effects of folic acid on disorders other than neural-tube defects].Ned Tijdschr Geneeskd. 2006 Nov 18;150(46):2571-2; author reply 2572. Ned Tijdschr Geneeskd. 2006. PMID: 17152336 Dutch. No abstract available.
-
Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.Am Heart J. 2006 Feb;151(2):282-7. doi: 10.1016/j.ahj.2005.04.025. Am Heart J. 2006. PMID: 16442889 Review.
-
Homocysteine and cardiovascular risk: considering the evidence in the context of study design, folate fortification, and statistical power.Clin Chem. 2007 May;53(5):807-9. doi: 10.1373/clinchem.2007.085480. Clin Chem. 2007. PMID: 17468406 No abstract available.
-
[No scientific evidence supports vitamin B treatment of patients with cardiovascular diseases].Lakartidningen. 2006 Nov 8-14;103(45):3464-6. Lakartidningen. 2006. PMID: 17140177 Review. Swedish. No abstract available.
-
Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?Atherosclerosis. 2002 Nov;165(1):1-3. doi: 10.1016/s0021-9150(02)00191-0. Atherosclerosis. 2002. PMID: 12208464 Review. No abstract available.
Cited by
-
Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.Lancet Neurol. 2012 Jun;11(6):512-20. doi: 10.1016/S1474-4422(12)70091-1. Epub 2012 May 2. Lancet Neurol. 2012. PMID: 22554931 Free PMC article. Clinical Trial.
-
The Effects of Folic Acid Administration on Cardiac Oxidative Stress and Cardiovascular Biomarkers in Diabetic Rats.Oxid Med Cell Longev. 2019 Jun 11;2019:1342549. doi: 10.1155/2019/1342549. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31308875 Free PMC article.
-
Epigenetic associations in relation to cardiovascular prevention and therapeutics.Clin Epigenetics. 2016 Jan 15;8:4. doi: 10.1186/s13148-016-0170-0. eCollection 2016. Clin Epigenetics. 2016. PMID: 26779291 Free PMC article. Review.
-
A cost-effectiveness analysis of folic acid fortification policy in the United States.Public Health Nutr. 2009 Apr;12(4):455-67. doi: 10.1017/S1368980008002565. Epub 2008 Jul 1. Public Health Nutr. 2009. PMID: 18590584 Free PMC article.
-
Micronutrient status in patients with diabetic foot ulcers: A cross-sectional study in Saudi Arabia.J Family Med Prim Care. 2024 Jan;13(1):356-362. doi: 10.4103/jfmpc.jfmpc_1109_23. Epub 2024 Feb 8. J Family Med Prim Care. 2024. PMID: 38482321 Free PMC article.
References
-
- Homocysteine Studies Collaboration. Homocysteine and the risk of ischemic heart disease and stroke. JAMA 2002;288:2015-22. - PubMed
-
- Kluijtmans LAJ, Boers GHD, Kraus JP, van den Heuvel LP, Cruysberg JR, Trijbels FJ, et al. The molecular basis of cystathionine β synthase deficiency in Dutch patients with homocystinuria: effect of SBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet 1999;65:59-67. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical